Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis.

Antimicrobial Agents and Chemotherapy
A E StuckE Weidekamm

Abstract

The pharmacokinetics of fleroxacin, including the formation of N-demethyl and N-oxide fleroxacin after the administration of single intravenous (100-mg) and oral (400-mg) doses, was investigated in 26 subjects with various levels of renal function, including 7 patients on continuous ambulatory peritoneal dialysis. Fleroxacin was well tolerated by all subjects. The volume of distribution, systemic availability, and peak concentration after the administration of oral fleroxacin were independent of the glomerular filtration rate. As a consequence of a declining renal clearance but not nonrenal clearance, the total body clearance of fleroxacin declined with decreasing glomerular filtration rate from 1.41 +/- 0.23 ml/min per kg in subjects with normal renal function to 0.58 +/- 0.13 ml/min per kg in patients with end-stage renal disease (r = 0.84, P less than 0.001). The analysis revealed that the N-oxide metabolite exhibited formation-limited kinetics and the N-demethyl metabolite exhibited elimination-limited kinetics. The areas under the curve of both metabolites increased with declining renal function. In patients on continuous ambulatory peritoneal dialysis the mean dialysate/plasma concentration ratio of fleroxacin increased f...Continue Reading

References

Nov 1, 1985·Antimicrobial Agents and Chemotherapy·D C Hooper, J S Wolfson
Apr 1, 1986·Antimicrobial Agents and Chemotherapy·N X ChinH C Neu
Feb 1, 1987·Antimicrobial Agents and Chemotherapy·R WiseD J Griggs
Dec 1, 1987·Antimicrobial Agents and Chemotherapy·E WeidekammP W Lücker
Mar 1, 1985·Antimicrobial Agents and Chemotherapy·G HöffkenP Koeppe
May 1, 1987·Antimicrobial Agents and Chemotherapy·T C GasserP O Madsen
Sep 1, 1987·Antimicrobial Agents and Chemotherapy·H LodeP Koeppe
Jun 1, 1987·Chemioterapia : International Journal of the Mediterranean Society of Chemotherapy·W CouetG Humbert
Jun 1, 1987·Antimicrobial Agents and Chemotherapy·G L DrusanoH C Standiford
Mar 1, 1982·Journal of Pharmaceutical Sciences·D Perrier, M Mayersohn

❮ Previous
Next ❯

Citations

Jan 1, 1993·International Journal of Antimicrobial Agents·W CullmannA Braunsteiner
Jun 1, 1994·Antimicrobial Agents and Chemotherapy·J SchrenzelD P Lew
Mar 23, 2012·Expert Opinion on Drug Metabolism & Toxicology·Aditi MulgaonkarDouglas H Sweet
Oct 3, 1998·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J VincentR Teng
Jan 8, 2003·Biopharmaceutics & Drug Disposition·Peter H Hinderling
Aug 1, 1996·Antimicrobial Agents and Chemotherapy·D E UehlingerF J Frey

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.